Tumor Necrosis Factor Inhibitor Drugs Market
Tumor Necrosis Factor Inhibitor Drugs Market Size, Share & Industry Analysis, By Drug Type (Adalimumab, Infliximab, Etanercept, Certolizumab Pegol, Golimumab), By Application (Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis, Others), By Route of Administration (Subcutaneous, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa): Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview
The Tumour necrosis factor inhibitor drug market is expected to develop at a CAGR of 4.5% between 2024 and 2031. The market value is predicted to rise from XX USD in 2024 to YY USD in 2031. North America currently dominates the market, owing to its high frequency of autoimmune illnesses and modern healthcare infrastructure. Key metrics include increased R&D activity, increased biologics adoption, and increased awareness of autoimmune illnesses.
The market is steadily expanding due to the rising prevalence of inflammatory illnesses such as rheumatoid arthritis and psoriasis. Technological developments in drug delivery technologies as well as the introduction of biosimilars are helping to drive market growth. However, the high cost of TNF inhibitor medications and severe side effects may limit growth to some extent.
Market Dynamics
Market Trend: Increasing adoption of biosimilars driving market growth
The tumour necrosis factor inhibitor medicines industry is seeing a considerable shift towards the use of biosimilars. As the patents on original biologics expire, pharmaceutical companies are creating biosimilar TNF inhibitors. These biosimilars deliver equivalent efficacy at a cheaper cost, appealing to both healthcare professionals and patients. The introduction of biosimilars is increasing access to TNF inhibitor medicines, especially in emerging economies where cost has been a significant barrier. This trend is altering the competitive landscape and propelling overall market expansion by expanding patient access and treatment alternatives.
Market Driver: Rising prevalence of autoimmune disorders fuelling demand
The growing prevalence of autoimmune illnesses worldwide is a primary driver of the tumour necrosis factor inhibitor medicines industry. Millions of individuals worldwide suffer from conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, and their prevalence is increasing. For example, recent epidemiological data suggest that the global prevalence of rheumatoid arthritis is between 0.5 and 1% of the population, with around 5 million new cases diagnosed each year. TNF inhibitors have proven to be particularly effective in treating various disorders, resulting in rising prescription rates. The ageing population and changing lifestyles contribute to an increase in the burden of autoimmune diseases, which drives market growth.
Market Restraint: High treatment costs limiting accessibility
The high cost of tumour necrosis factor inhibitor medications remains a key impediment to market expansion. These biologics are difficult to make and frequently require long-term treatment, resulting in significant costs for individuals and healthcare systems. In some areas, the annual cost of TNF inhibitor medication may surpass $20,000 per patient. This price load hinders accessibility, especially in poor countries and among uninsured or underinsured people. While biosimilars are helping to bring down costs, the overall cost of TNF inhibitor medication remains a barrier to market expansion and patient access.
Segment Overview
Adalimumab dominates the TNF inhibitor drug market, driven by its versatility and efficacy across multiple indications.
Adalimumab, sold under a variety of brand names, has retained its position as the leading TNF inhibitor medicine in terms of market share and income. Its success is due to its wide variety of approved indications, which include rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The drug's efficacy, paired with its easy subcutaneous administration, has made it a popular choice among both healthcare practitioners and patients.
Recent clinical trials have broadened adalimumab's possible usage. Phase III research published in the New England Journal of Medicine found it effective in treating moderate to severe hidradenitis suppurativa, a chronic inflammatory skin condition. This new indication has created new market potential for Adalimumab.
The introduction of biosimilar versions of adalimumab has also changed the market environment. Major pharmaceutical companies have introduced adalimumab biosimilars in several locations, enhancing competition and potentially improving patient access. For example, in Europe, where biosimilar adoption has been robust, adalimumab biosimilars have acquired a large market share, with certain countries reporting biosimilar uptake rates of more than 50% within two years of release.
Regional Outlook
North America leads the tumor necrosis factor inhibitor drugs market, driven by high disease prevalence and advanced healthcare infrastructure.
North America, notably the United States, dominates the global TNF inhibitor medicines market. This dominance is due to a variety of variables, including a large frequency of autoimmune illnesses, well-established healthcare systems, and favourable reimbursement regulations. The region also benefits from the presence of large pharmaceutical businesses as well as ongoing biologics research and development.
According to recent market data, the United States accounts for more than 40% of global income from TNF inhibitor medications. Adoption of these medications has been particularly significant in rheumatology and dermatological practices nationwide.
The prescription rate for TNF inhibitors among rheumatoid arthritis patients is an important statistic that highlights the market's strength in North America. According to a recent poll of rheumatologists, around 30% of rheumatoid arthritis patients in the United States are currently using a TNF inhibitor medication.
The regulatory environment in North America has also proven conducive to market expansion. The FDA has approved additional indications for current TNF inhibitors and introduced newer formulations, expanding therapy options. For example, the recent approval of a citrate-free, high-concentration formulation of adalimumab has enhanced patients' injection experience, potentially increasing adherence and market penetration.
Competitive Intelligence
The tumour necrosis factor inhibitor medicines market is fiercely competitive, with a few prominent manufacturers dominating the area. These companies are constantly conducting research and development to grow their product portfolios and maintain their market positions. Firms frequently engage in strategic collaborations, mergers, and acquisitions to improve their pipelines and worldwide reach.
Market leaders have been working to create next-generation TNF inhibitors with enhanced efficacy and safety characteristics. Some companies are investigating combination treatments, which combine TNF inhibitors with other immunomodulators to improve treatment outcomes. As patents for original biologics expire, multiple firms enter the market, making the biosimilar category more competitive.
Financial success differs across prominent players, with some reporting significant increases in their immunology portfolios. For example, one top company reported a 10% year-over-year growth in global sales of its flagship TNF inhibitor medicine during the previous fiscal year. Market shares are steadily shifting as a result of biosimilar competition, with originators employing a variety of methods to protect their positions, such as price modifications and value-added services.
Looking ahead, the competitive landscape is anticipated to change further with the potential arrival of new firms and the development of novel therapeutic approaches targeting the TNF pathway. Companies are also investing in innovative medicine delivery methods and patient care programs to differentiate their products in an increasingly competitive industry.
Analyst Opinion
The market for tumour necrosis factor inhibitor medications is expected to increase further, owing to the rising prevalence of autoimmune illnesses and the expanding indications for these therapies. However, the market is undergoing upheaval as biosimilar competition reshapes the competitive landscape and pricing dynamics.
The development of bispecific antibodies that target TNF as well as other inflammatory mediators is an emerging trend worth keeping an eye on. These new medicines may have better efficacy and safety characteristics than standard TNF inhibitors. Furthermore, developments in biomarker research are anticipated to influence treatment patterns and drug development methods in the next few years, contributing to a trend towards personalised medicine.
Major Players
-
AbbVie Inc.
-
Johnson & Johnson
-
Amgen Inc.
-
Pfizer Inc.
-
Novartis AG
-
UCB S.A.
-
Bristol-Myers Squibb Company
-
Merck & Co., Inc.
-
Biogen Inc.
-
Samsung Bioepis Co., Ltd.
Key Developments
-
May 2023: FDA approval of a new autoinjector device for a major TNF inhibitor, improving ease of administration for patients.
-
February 2024: Launch of a novel TNF inhibitor biosimilar in European markets, expanding patient access to treatment.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. AbbVie Inc.
5.2. Johnson & Johnson
5.3. Amgen Inc.
5.4. Pfizer Inc.
5.5. Novartis AG
5.6. UCB S.A.
5.7. Bristol-Myers Squibb Company
5.8. Merck & Co., Inc.
5.9. Biogen Inc.
5.10. Samsung Bioepis Co., Ltd. (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Increasing adoption of biosimilars driving market growth
6.1.2. Development of bispecific antibodies targeting TNF
6.1.3. Shift towards personalised medicine in autoimmune disorders
6.2. Market Drivers
6.2.1. Rising prevalence of autoimmune disorders fuelling demand
6.2.2. Expanding indications for TNF inhibitor drugs
6.2.3. Technological advancements in drug delivery systems
6.3. Market Restraints
6.3.1. High treatment costs limiting accessibility
6.3.2. Potential side effects and safety concerns
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Adalimumab
7.1.1. Branded
7.1.2. Biosimilars
7.2. Infliximab
7.2.1. Branded
7.2.2. Biosimilars
7.3. Etanercept
7.3.1. Branded
7.3.2. Biosimilars
7.4. Certolizumab pegol
7.5. Golimumab
8. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2020-2031)
8.1. Rheumatoid Arthritis
8.2. Psoriasis
8.3. Inflammatory Bowel Disease
8.3.1. Crohn's Disease
8.3.2. Ulcerative Colitis
8.4. Ankylosing Spondylitis
8.5. Others
9. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Subcutaneous
9.2. Intravenous
10. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online pharmacies
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%, YOY GROWTH)--2020-2031.
Tumor necrosis factor inhibitor Drug Market Segmentation
By Drug Type:
-
Adalimumab
-
Infliximab
-
Etanercept
-
Certolizumab pegol
-
Golimumab
By Application:
-
Rheumatoid arthritis
-
Psoriasis
-
Inflammatory Bowel Disease
-
Ankylosing Spondylitis
-
Others
By Route of Administration:
-
Subcutaneous
-
Intravenous
By Distribution Channel:
-
Hospital Pharmacies
-
Retail pharmacies
-
Online pharmacies
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511